Trials / Completed
CompletedNCT04609930
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 143 (actual)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-PD-1 or anti-PD-L1 | Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1. |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2020-10-30
- Last updated
- 2021-12-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04609930. Inclusion in this directory is not an endorsement.